Home
KRYS
KRYS News

Latest Krystal Biotech Inc. (KRYS) News on November 28, 2025

Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT

Insider Monkey

10 days ago

Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

GlobeNewswire

a month ago

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

MT Newswires

a month ago

BofA Securities Adjusts Krystal Biotech Price Target to $255 From $182, Maintains Buy Rating

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks in the US Market

TSCM U.S. Small Cap Growth Strategy Reduced Its Position in Krystal Biotech (KRYS)

Insider Monkey

3 months ago

TSCM U.S. Small Cap Growth Strategy Reduced Its Position in Krystal Biotech (KRYS)

MT Newswires

3 months ago

Chardan Trims Price Target on Krystal Biotech to $216 From $219, Keeps Buy Rating

MT Newswires

3 months ago

Krystal Biotech to Prioritize Inhaled KB707 for Treatment of Non-Small Cell Lung Cancer

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

GlobeNewswire

3 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

3 Promising Genomics Stocks to Keep an Eye On in 2025

Zacks

5 months ago

3 Promising Genomics Stocks to Keep an Eye On in 2025

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

Zacks

5 months ago

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

Zacks

5 months ago

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

GlobeNewswire

5 months ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Argus Research

6 months ago

KRYS: Raising target price to $152.00

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?

Zacks

6 months ago

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?

Exploring Three High Growth Tech Stocks In The US Market

Simply Wall St.

6 months ago

Exploring Three High Growth Tech Stocks In The US Market

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire

6 months ago

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Three Insider-Favored Growth Companies To Watch

Simply Wall St.

6 months ago

Three Insider-Favored Growth Companies To Watch

Implied Volatility Surging for Krystal Biotech Stock Options

Zacks

6 months ago

Implied Volatility Surging for Krystal Biotech Stock Options

Argus Research

6 months ago

KRYS: Lowering target price to $145.00

Argus Research

6 months ago

KRYS: Lowering target price to $148.00

Krystal Biotech's (NASDAQ:KRYS) Solid Earnings Have Been Accounted For Conservatively

Simply Wall St.

6 months ago

Krystal Biotech's (NASDAQ:KRYS) Solid Earnings Have Been Accounted For Conservatively

Biotech Alert: Searches spiking for these stocks today

TipRanks

7 months ago

Biotech Alert: Searches spiking for these stocks today

Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Insider Monkey

7 months ago

Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

GlobeNewswire

7 months ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

Krystal Biotech First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

7 months ago

Krystal Biotech First Quarter 2025 Earnings: Misses Expectations

Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

7 months ago

Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

Argus Research

7 months ago

KRYS: Lowering target price to $153.00

Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down

Zacks

7 months ago

Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down

Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates

Zacks

7 months ago

Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates

MT Newswires

7 months ago

Krystal Biotech's Q1 Earnings, Revenue Rise

Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

GlobeNewswire

7 months ago

Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

Krystal Biotech Inc (KRYS) Q1 2025 Earnings Report Preview: What to Look For

GuruFocus.com

7 months ago

Krystal Biotech Inc (KRYS) Q1 2025 Earnings Report Preview: What to Look For

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks

7 months ago

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Zacks

7 months ago

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Abeona cell therapy approved by FDA for rare skin condition

BioPharma Dive

7 months ago

Abeona cell therapy approved by FDA for rare skin condition

MT Newswires

7 months ago

Krystal Biotech Gets EU Approval to Market Treatment for Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire

7 months ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at Upcoming Scientific Conferences

GlobeNewswire

7 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Argus Research

7 months ago

KRYS: What does Argus have to say about KRYS?

Top Growth Companies With High Insider Ownership In April 2025

Simply Wall St.

7 months ago

Top Growth Companies With High Insider Ownership In April 2025

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

GlobeNewswire

7 months ago

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

Argus Research

7 months ago

KRYS: Raising target price to $186.00

Argus Research

8 months ago

KRYS: Lowering target price to $175.00

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Zacks

8 months ago

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

GlobeNewswire

8 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

Zacks

8 months ago

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

Argus Research

8 months ago

KRYS: Lowering target price to $204.00

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Zacks

8 months ago

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Argus Research

8 months ago

KRYS: Rating increased to a BUY

US High Growth Tech Stocks With Promising Potential

Simply Wall St.

8 months ago

US High Growth Tech Stocks With Promising Potential

3 High Growth Companies Insiders Are Betting On

Simply Wall St.

8 months ago

3 High Growth Companies Insiders Are Betting On

Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

Zacks

8 months ago

Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

Zacks

8 months ago

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

MT Newswires

8 months ago

Krystal Biotech Insider Sold Shares Worth $8,889,525, According to a Recent SEC Filing

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

Zacks

9 months ago

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

MT Newswires

9 months ago

Jefferies Initiates Krystal Biotech at Buy With $245 Price Target

Argus Research

9 months ago

KRYS: Lowering target price to $184.00

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Zacks

9 months ago

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Solid Earnings Reflect Krystal Biotech's (NASDAQ:KRYS) Strength As A Business

Simply Wall St.

9 months ago

Solid Earnings Reflect Krystal Biotech's (NASDAQ:KRYS) Strength As A Business

MT Newswires

9 months ago

Krystal Biotech's Skin Disorder Treatment Recommended by European Medicines Agency Committee

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire

9 months ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire

9 months ago

Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference

Argus Research

9 months ago

KRYS: Raising target price to $190.00

Why Krystal Biotech (KRYS) Might be Well Poised for a Surge

Zacks

9 months ago

Why Krystal Biotech (KRYS) Might be Well Poised for a Surge

Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term

Zacks

9 months ago

Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term

Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know

Zacks

9 months ago

Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know

Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up

Zacks

9 months ago

Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up

3 US Growth Companies With High Insider Ownership Expecting Up To 68% Earnings Growth

Simply Wall St.

9 months ago

3 US Growth Companies With High Insider Ownership Expecting Up To 68% Earnings Growth

Krystal Biotech Inc (KRYS) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

GuruFocus.com

9 months ago

Krystal Biotech Inc (KRYS) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

Thomson Reuters StreetEvents

9 months ago

Q4 2024 Krystal Biotech Inc Earnings Call

High Growth Tech Stocks in United States to Watch

Simply Wall St.

9 months ago

High Growth Tech Stocks in United States to Watch

MT Newswires

9 months ago

Sector Update: Health Care Stocks Steady Premarket Wednesday

MT Newswires

9 months ago

Krystal Biotech Q4 Net Income, Revenue Rise

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

GlobeNewswire

9 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Krystal Biotech Inc (KRYS) Q4 2024 Earnings Report Preview: What to Look For

GuruFocus.com

9 months ago

Krystal Biotech Inc (KRYS) Q4 2024 Earnings Report Preview: What to Look For

Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?

Zacks

10 months ago

Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?

Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

GlobeNewswire

10 months ago

Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Argus Research

10 months ago

KRYS: Raising target price to $169.00

Argus Research

10 months ago

KRYS: Raising target price to $167.00

Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock?

Zacks

10 months ago

Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock?

US Growth Companies With High Insider Ownership In January 2025

Simply Wall St.

10 months ago

US Growth Companies With High Insider Ownership In January 2025

Argus Research

10 months ago

KRYS: Raising target price to $159.00

High Growth Tech Stocks to Watch in January 2025

Simply Wall St.

10 months ago

High Growth Tech Stocks to Watch in January 2025

Argus Research

10 months ago

KRYS: Lowering target price to $150.00

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

GlobeNewswire

10 months ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

Simply Wall St.

a year ago

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

Argus Research

a year ago

KRYS: Lowering target price to $169.00

Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Simply Wall St.

a year ago

Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Zacks

a year ago

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

MT Newswires

a year ago

Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Argus Research

a year ago

KRYS: Lowering target price to $177.00

MT Newswires

a year ago

Krystal Biotech Insider Sold Shares Worth $8,240,023, According to a Recent SEC Filing

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Zacks

a year ago

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech announces initial update for KB408, KB407

TipRanks

a year ago

Krystal Biotech announces initial update for KB408, KB407

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Zacks

a year ago

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

GlobeNewswire

a year ago

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

Argus Research

a year ago

KRYS: What does Argus have to say about KRYS?

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

GlobeNewswire

a year ago

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?

Zacks

a year ago

Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?

Share on Social Networks: